955 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Dahi
    Dahi
  4. Ponce
    Ponce
  5. Shah
    Shah
  6. Sauter
    Sauter
  7. Jakubowski
    Jakubowski
  8. Papadopoulos
    Papadopoulos
  9. Devlin
    Devlin
  10. Scordo
    Scordo

Groups

  1. CTCR Scholars (955)
  2. MSK Grad Students (955)
  3. Master of Science in Clinical and Translational Cancer Research (955)
  4. Department of Medicine (853)
  5. Hematologic Malignancies, Division of (651)
  6. Center for Hematologic Malignancies (630)
  7. Survivorship Research (578)
  8. Bone Marrow Transplant (574)
  9. Epidemiology and Biostatistics (453)
  10. Biostatistics Service (414)
  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (519)
  2. Journal Article (329)
  3. Review (40)
  4. Miscellaneous (16)
  5. Research Letter (15)
  6. Editorial (14)
  7. Correspondence (12)
  8. Conference Paper (4)
  9. Book Section (3)
  10. Guidelines (3)
Groups
  1. CTCR Scholars (955)
  2. MSK Grad Students (955)
  3. Master of Science in Clinical and Translational Cancer Research (955)
  4. Department of Medicine (853)
  5. Hematologic Malignancies, Division of (651)
  6. Center for Hematologic Malignancies (630)

More Groups

People
  1. Sergio Giralt (378)
  2. Miguel-Angel Perales (356)
  3. Parastoo Dahi (294)
  4. Sean Devlin (265)
  5. Doris Ponce (254)
  6. Roni Tamari (208)

More People

Years
  1. 2025 (41)
  2. 2024 (109)
  3. 2023 (140)
  4. 2022 (121)
  5. 2021 (104)
  6. 2020 (119)

More Years

Publications
  1. Blood (191)
  2. Biology of Blood and Marrow Transplantation (153)
  3. Journal of Clinical Oncology (79)
  4. Annals of Surgical Oncology (78)
  5. Bone Marrow Transplantation (55)
  6. Transplantation and Cellular Therapy (42)

More Publications

Publishers
  1. American Society of Hematology (223)
  2. Elsevier Inc. (219)
  3. Springer (90)
  4. American Society of Clinical Oncology (87)
  5. Nature Publishing Group (82)
  6. American Association for Cancer Research (29)

More Publishers

Results (955)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study
    Meeting Abstract

    Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of eprenetapopt (APR-246) in combination with azacitidine (AZA) as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplantation (SCT)
    Meeting Abstract

    Mishra, A.; Tamari, R.; DeZern, A. E.; Byrne, M. T.; Gooptu, M.; Chen, Y. B.; Deeg, H. J.; Gallacher, P.; Wennborg, A.; Hickman, D. K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim results of a pilot, prospective, randomized, double-blinded, vehicle- and comparator-controlled trial on safety and efficacy of a topical inhibitor of janus kinase 1/2 (ruxolitinib INCB018424 phosphate 1.5% cream) for non- sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease
    Meeting Abstract

    Markova, A.; Pan, A.; Dusza, S.; Chowdhury, A.; Kukoyi, O.; Perales, M. A.; Lacouture, M.; Prockop, S.; Ponce, D. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G.; Kim, H. T.; Bottoms, A. J. S.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Defilipp, Z.; El-Jawahri, A.; McAfee, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Racial disparities in access to alternative donor allografts persist in the era of "Donors for all"
    Meeting Abstract

    Fingrut, W.; Politikos, I.; Davis, E.; Chinapen, S.; Naputo, K.; Cho, C.; Giralt, S. A.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save